In a study of patients with ankylosing spondylitis (AS), the rate of anterior uveitis was reduced upon treatment with adalimumab (n = 406) or infliximab (n = 605) compared with pretreatment rates. The opposite was seen in patients receiving etanercept treatment (n = 354). Treatment with etanercept was associated with an increased risk of anterior uveitis compared with adalimumab (HR 3.86, 95% CI 1.85–8.06) or influximab (HR 1.99, 95% CI 1.23–3.22), whereas no significant differences were observed between adalimumab and infliximab treatment.
References
Lie, E. et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-210931 (2017)
Rights and permissions
About this article
Cite this article
McHugh, J. Monitoring risk of anterior uveitis in AS. Nat Rev Rheumatol 13, 258 (2017). https://doi.org/10.1038/nrrheum.2017.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.48